Elena Ridloff Biography and Net Worth

Director of Kymera Therapeutics

Elena Ridloff has over 20 years of experience in finance and the life sciences industry. She is currently the Chief Financial Officer of a stealth biotechnology company. Previously she was Executive Vice President and Chief Financial Officer for ACADIA Pharmaceuticals where she was responsible for leading corporate finance, accounting, investor relations and corporate affairs functions. Prior to joining Acadia, Ms. Ridloff was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee. Additionally, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm serving the life sciences industry. She was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device, and life science sectors. She currently serves on the Board of Directors of Kronos Bio, Inc.

Ms. Ridloff received her BA in History and Sociology of Science from the University of Pennsylvania. She is also a CFA© charterholder.

What is Elena Ridloff's net worth?: The estimated net worth of Elena Ridloff is at least $2.55 million as of September 2nd, 2025. Ms. Ridloff owns 38,532 shares of Kymera Therapeutics stock worth more than $2,551,974 as of December 4th. This net worth estimate does not reflect any other assets that Ms. Ridloff may own. Learn More about Elena Ridloff's net worth.
How do I contact Elena Ridloff?: The corporate mailing address for Ms. Ridloff and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Elena Ridloff's contact information.
Has Elena Ridloff been buying or selling shares of Kymera Therapeutics?: Elena Ridloff has not been actively trading shares of Kymera Therapeutics during the past quarter. Most recently, Elena Ridloff sold 12,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a transaction totalling $553,200.00. Learn More on Elena Ridloff's trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Jeremy Chadwick (COO), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), Nello Mainolfi (CEO), and Elena Ridloff (Director). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, Kymera Therapeutics insiders bought shares 2 times. They purchased a total of 972,667 shares worth more than $42,797,348.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 269,047 shares worth more than $14,192,151.22. The most recent insider tranaction occured on October, 29th when CEO Nello Mainolfi sold 30,000 shares worth more than $1,829,700.00. Insiders at Kymera Therapeutics own 16.0% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 10/29/2025.

Elena Ridloff Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/3/2025	Sell	12,000	$46.10	$553,200.00

Elena Ridloff Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $66.23

$65.24

$68.78

50 Day Range

MA: $61.27

$54.66

$69.67

2 Week Range

Now: $66.23

$19.44

$68.80

Volume

741,618 shs

Average Volume

678,646 shs

Market Capitalization

$4.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28